Shopping cart
An Effective and Safe Supplement for Stem Cells Expansion ex vivo - Cord Blood Serum
Authors: Hai-ying Ma, Li Yao, Yan-qiu Yu, Li Li, Ling Ma, Wen-juan Wei, Xiao-mei Lu, Li-li Du, Yu-nan Jin
Source: Cell Transplantation
Publisher: Cognizant Communication Corporation
Buy & download fulltext article:
The full text is free.
View now:
Abstract:
Mesenchymal stem cells (MSCs) are potential and optimal stem cells in clinical cell therapy, and fetal bovine serum (FBS) is widely used for MSCs expansion, despite the risks of infectious disease transmission and immunological reaction of the xenogenic origin. This study was to compare human four blood groups cord blood serum (CBS) with FBS in culturing human placenta-derived mesenchymal stem cells (hPDMSCs), which were derived from four blood groups donors. The expansion medium included: 10%FBS, 10% A-CBS, 10%B-CBS, 10%O-CBS and 10% AB-CBS. Cumulative population doubling, generation time, fold expansion rates and differentiation capacity, cell cycle and immunophenotype were also assessed. The result showed that fold expansion rate and cumulative population doubling of hPDMSCs significantly increased during long term MSCs expansion in CBS medium, but the generation time decreased compared with FBS. CBS might be an effective supplement for stem cells expand rapidly ex vivo. Cell cycle and differentiation assays showed that most of hPDMSCs expanding in the presence of CBS were in stationary phase, which was the characteristic of stem cells, and that retained their ability to differentiate into chondrogenic and endothelial cells. By comparing these four blood groups of CBS, we found that there was no significant difference among different blood groups in culturing hPDMSCs, which were isolated from different blood groups donors. So CBS may be an optimal replacement to avoid the risks of FBS application in expansion of stem cell for clinical cells therapy and tissue engineering.Document Type:
DOI: http://dx.doi.org/10.3727/096368911X612486
Appeared or available online: December 13, 2011
Key
Print this page